Troy hyperbaric chamber tragedy prompts investigation into Oxford Center practices
The Brief
A mother lost her son from a hyperbaric chamber fire in Troy, prompting an investigation.
Officials say concerns have been raised about the lack of maintenance and oversight.
The Oxford Center remains under investigation following the tragic incident.
TROY, Mich. (FOX 2) - It was a mother's desperate attempt to save her little boy who was trapped inside a hyperbaric chamber with burning flames in Troy.
The backstory
A helpless feeling a parent can't even imagine. Attorney James Harrington is working to make sure nobody else will.
"She rushed back to where her son was to find him engulfed in flames, and she was doing everything possible to get him out while sustaining significant burns to her arm," he said.
Harrington is representing the parents of Thomas Cooper and, along with Troy police and the state, investigating what went wrong and who is responsible.
What they're saying
Sources tell FOX 2 the center was understaffed that day. There were three patients receiving oxygen therapy, which meant there should have been three technicians. Officials say there was only one.
Meanwhile, there are issues regarding the maintenance of the hyperbaric oxygen chambers.
Sechrist Industries hasn't responded to FOX 2's request for required maintenance of their medical technology used by the Oxford Center, but it appears any facility that can afford to buy the hyperbaric chambers basically uses the honor system, since there is no state oversight.
"This is a big issue. There is no accreditation, no state oversight. The more things that they say that they can fix, or the things that they can treat, the more customers and don't forget that this is a for-profit enterprise," said Harrington.
Dig deeper
Because there is also no proven science backing oxygen therapy for the conditions listed on the Oxford Center's site, insurance doesn't cover it. The Coopers paid eight thousand dollars for 40 oxygen therapy sessions for Thomas, who they were told would help his ADHD and sleep apnea.
"They took all their names and faces off of their website in the last few days after this event so, they know that there is a problem – of course they do," Harrington said.
That's also what happened after FOX 2's first special report on the medical facility back in 2021.
In fact, the founder, Tami Peterson, changed the name from Oxford Recovery Center with locations in Brighton and Troy to the Oxford Center.
Timeline
That was when FOX 2 revealed she hired convicted felon Casey Coden Diskin, who lied about her experience, had stolen medical credentials, and posed as a certified BCBA therapist and ran a program that treated the most vulnerable autistic children.
In response, owner and founder Tami Peterson sent me this letter, which read in part:
We are aware of Ms. Diskin's past. As an organization founded by Christians, we believe in forgiveness and redemption. Whatever challenges she faced in the past, she has been an exemplary employee.
Fast-forward, the AG's office charged Casey Coden Diskin with 18 felonies. In 2024, she pleaded guilty and has since been sentenced to almost eight years in prison.
What's next
What else has been going on inside the Oxford Centers is still under investigation by the state and now the tragic death of Thomas Cooper.
The Source
FOX 2 talked with Attorney James Harrington and used information from previous stories.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 15, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release capsules) and granted it Priority Review designation. The investigational therapeutic drug is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged six years and above. First Methylphenidate Combination Drug Poised to Benefit Patients in China Azstarys (AK0901) is the first and currently the sole globally approved ADHD combination therapeutic pairing immediate-release dexmethylphenidate (d-MPH) with the prodrug serdexmethylphenidate (SDX). Approved by the U.S. FDA in 2021, Azstarys represents a new generation of methylphenidate medications, providing a dual-phase release profile that offers both rapid onset and sustained symptom control. This novel formulation sets a new benchmark in the management of ADHD for safety, efficacy, and convenience of administering for patients, making it a potential best-in-class ADHD therapeutic drug. Pharmacokinetic Property: Biphasic Release for Rapid Onset and Whole-Day Symptom Control Rapid onset: Immediate-release d-MPH ensures symptom relief within 30 minutes, offering fast control over core ADHD symptoms. Extended control: SDX is metabolized slowly into d-MPH in intestine over time, ensuring up to 13 hours of therapeutic effect with reduced risk of evening rebound symptoms. Stable Release Profile: Designed to support the full span of a patient's day—from school or work to evening activities—Azstarys enhances adherence and minimizes sleep disruptions, suiting both pediatric and adult populations. Abuse-Deterrent Design Azstarys incorporates an inherent abuse-deterrent design through the inclusion of SDX, which undergoes slow conversion in the gastrointestinal tract. This limits peak plasma concentrations of d-MPH and significantly reduces the potential for misuse via non-oral routes—a key public health consideration in ADHD pharmacotherapy. Robust Clinical Efficacy and Safety Confirmed in China Phase III Trial In a multicenter Phase III trial spanning eight leading clinical hospitals in China, Azstarys demonstrated statistically significant improvements over placebo in primary and secondary efficacy endpoints. The study reported no drug related serious adverse events, affirming Azstarys's favorable safety and tolerability profile, critical for long-term use in pediatric settings. Transforming ADHD Treatment Paradigm in China As the third-generation methylphenidate therapy, Azstarys delivers a new standard of care in ADHD management by integrating rapid onset and full-day symptom control into a single dose. Its future approval in China would mark the introduction of the first ADHD combination medication to the market, offering a better option for patients, families, and physicians. Dr. Jim Wu, CEO of ArkBio, stated, "The acceptance of Azstarys' NDA and its designation for Priority Review by the NMPA reflect regulatory authority's favorable opinions in our science and clinical study results. ADHD remains critically underserved in China, and Azstarys is designed to directly meet the needs of patients who require both immediate symptom relief and sustained control. We are grateful to our investigators, trial participants, collaborators, and the NMPA for this milestone and we look forward to accelerating access to this important therapeutic in China market." Azstarys® is a registered trademark of Corium, LLC in the United States. About ArkBio ArkBio is a global biotech company focused on developing innovative therapeutics for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir (AK0529), the first direct-acting RSV antiviral with positive pivotal phase III results, and Azstarys (AK0901), an FDA-approvedADHD therapeutic drug. ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information about the company, please visit our website: View original content to download multimedia: SOURCE Arkbio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 15, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release capsules) and granted it Priority Review designation. The investigational therapeutic drug is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged six years and above. First Methylphenidate Combination Drug Poised to Benefit Patients in China Azstarys (AK0901) is the first and currently the sole globally approved ADHD combination therapeutic pairing immediate-release dexmethylphenidate (d-MPH) with the prodrug serdexmethylphenidate (SDX). Approved by the U.S. FDA in 2021, Azstarys represents a new generation of methylphenidate medications, providing a dual-phase release profile that offers both rapid onset and sustained symptom control. This novel formulation sets a new benchmark in the management of ADHD for safety, efficacy, and convenience of administering for patients, making it a potential best-in-class ADHD therapeutic drug. Pharmacokinetic Property: Biphasic Release for Rapid Onset and Whole-Day Symptom Control Rapid onset: Immediate-release d-MPH ensures symptom relief within 30 minutes, offering fast control over core ADHD symptoms. Extended control: SDX is metabolized slowly into d-MPH in intestine over time, ensuring up to 13 hours of therapeutic effect with reduced risk of evening rebound symptoms. Stable Release Profile: Designed to support the full span of a patient's day—from school or work to evening activities—Azstarys enhances adherence and minimizes sleep disruptions, suiting both pediatric and adult populations. Abuse-Deterrent Design Azstarys incorporates an inherent abuse-deterrent design through the inclusion of SDX, which undergoes slow conversion in the gastrointestinal tract. This limits peak plasma concentrations of d-MPH and significantly reduces the potential for misuse via non-oral routes—a key public health consideration in ADHD pharmacotherapy. Robust Clinical Efficacy and Safety Confirmed in China Phase III Trial In a multicenter Phase III trial spanning eight leading clinical hospitals in China, Azstarys demonstrated statistically significant improvements over placebo in primary and secondary efficacy endpoints. The study reported no drug related serious adverse events, affirming Azstarys's favorable safety and tolerability profile, critical for long-term use in pediatric settings. Transforming ADHD Treatment Paradigm in China As the third-generation methylphenidate therapy, Azstarys delivers a new standard of care in ADHD management by integrating rapid onset and full-day symptom control into a single dose. Its future approval in China would mark the introduction of the first ADHD combination medication to the market, offering a better option for patients, families, and physicians. Dr. Jim Wu, CEO of ArkBio, stated, "The acceptance of Azstarys' NDA and its designation for Priority Review by the NMPA reflect regulatory authority's favorable opinions in our science and clinical study results. ADHD remains critically underserved in China, and Azstarys is designed to directly meet the needs of patients who require both immediate symptom relief and sustained control. We are grateful to our investigators, trial participants, collaborators, and the NMPA for this milestone and we look forward to accelerating access to this important therapeutic in China market." Azstarys® is a registered trademark of Corium, LLC in the United States. About ArkBio ArkBio is a global biotech company focused on developing innovative therapeutics for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir (AK0529), the first direct-acting RSV antiviral with positive pivotal phase III results, and Azstarys (AK0901), an FDA-approvedADHD therapeutic drug. ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information about the company, please visit our website: View original content to download multimedia: SOURCE Arkbio
Yahoo
3 days ago
- Yahoo
Pharmacy Mixes Up 9-Year-Old's ADHD Medicine, Gives Him Opioid More Powerful Than Morphine
A 9-year-old boy nearly took a powerful opioid stronger than morphine after the local pharmacy gave them a prescription intended for someone else Sarah Paquin says her son usually takes dextroamphetamine for his ADHD, but when her husband went to give their son his medication, he realized it looked different A rep for Shoppers Drug Mart pharmacy in Comox, B.C., tells PEOPLE "the patient was handed the wrong prescription bag"A pharmacy mixed up a nine-year-old's ADHD medicine, giving him a powerfully addictive opioid meant for another customer instead. Sarah Paquin says her 9-year-old son, Declan, takes dextroamphetamine for his ADHD. It's a commonly prescribed stimulant that Declan had been taking for years. As Sarah tells PEOPLE, her husband, David, was about to give him the medication, which they'd picked up from Shoppers Drug Mart pharmacy in Comox, B.C., on May 28. "It's very chaotic in the morning, and if my husband had just been distracted with the other two, or been tired from being up with the baby the night before, this could have ended totally differently," Sarah, who has a 3-year-old and 10-month-old, tells PEOPLE. That's when David looked at the bottle, and realized he was holding someone else's prescription — and it was for hydromorphone. It's a profoundly strong opioid, the U.S. Drug Enforcement Agency explains, with 'potency approximately two to eight times greater than that of morphine and has a rapid onset of action.' As the National Library of Medicine says, 'Accidental ingestion or intentional abuse can lead to overdose and potentially life-threatening respiratory depression.' In a statement to PEOPLE, Loblaw Companies Ltd., which owns Shoppers Drug Mart, said, 'Upon review with the store, we have learned this was a case of human error, one that never should have happened. We have controls in place to minimize risks like this – where the patient was handed the wrong prescription bag – and the Associate will review these with employees to avoid a similar situation in the future. The owner of this location has reached out to the patient's parents to apologize for any undue stress this may have caused, and to outline the corrective steps.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "Thankfully my husband caught it before he took any of it," Sarah says, sharing the pills they'd been given were a 5 mg dose of the powerful opioid. "To do that to a 9-year-old child, it would have been devastating," she tells PEOPLE. She says her family has filed an official complaint with the College of Pharmacists of British Columbia a regulatory agency, and part of the complaint, she says, is "we would like some more strong and strict procedures put in place for picking up such strong heavy medications, especially when they pertain to a child." Her son's medicine, she said, was eventually found in the pharmacy's outgoing box. However, they won't be returning there for their prescriptions. "Trust has been broken," she tells PEOPLE, and urges everyone to inspect their medications before leaving the pharmacy: "Some simple little mistake like that can end somebody's life or cause serious harm." Read the original article on People